

Changing Medication-Related Beliefs: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Elizabeth Sheils¹, William Tillet^{1, 2}, Delyth James³, Sarah Brown³, Charlotte Dack⁴,
Hannah Family^{5, 6}, and Sarah C. E. Chapman^{1, 7}

¹Department of Life Sciences: Pharmacy and Pharmacology, University of Bath

²Royal National Hospital for Rheumatic Diseases, Royal United Hospital Bath, Bath, United Kingdom

³Department of Applied Psychology, Cardiff Metropolitan University

⁴Department of Psychology, University of Bath

⁵NIHR Health Protection Research Unit in Behavioural Science and Evaluation, University of Bristol

⁶The National Institute for Health and Care Research Applied Research Collaboration West,
University Hospitals Bristol and Weston NHS Foundation Trust

⁷Institute of Pharmaceutical Science, Kings College London

Objective: Medication-related beliefs, for example, beliefs that medicines are unnecessary or that side effects are likely, can influence medication behaviors and experiences, potentially impacting quality of life and mortality. At times, it may be useful to change medication-related beliefs, for example, to reduce patients' concerns about side effects when extensive evidence suggests side effects are rare. Currently we do not know the most effective methods to address medication beliefs. **Method:** Systematic review and meta-analysis of randomized controlled trials that measured medication-related beliefs in people prescribed medication for long-term condition(s). We extracted data on behavior change techniques (BCTs), belief measure, study and patient characteristics, risk of bias, and quality of description. **Results:** We identified 56 trials randomizing 8,714 participants. In meta-analysis, interventions led to small-to-medium effects ($n = 36$, Hedges' $g = .362$, 95% confidence interval [CI] [.20, .52], $p < .001$) in increasing beliefs about medication need/benefit and reducing concerns about medication ($n = 21$, Hedges' $g = -.435$, 95% CI [−0.72, −0.15], $p < .01$). Effect sizes were higher for interventions that reported a significant effect on adherence. Problem solving, information about health consequences, and social support (unspecified) were the most prevalent BCTs. Fourteen BCTs were associated with significant effects on need/benefit beliefs and four BCTs were associated with significant effects on concern beliefs. **Conclusion:** It is possible to modify medication-related beliefs using a range of interventions and techniques. Future research should explore the best ways to operationalize these BCTs for specific health conditions to support medication beliefs and improve adherence.

Public Significance Statement

This review advances the field through highlighting techniques that can lead to a change in medication beliefs and as a consequence improved adherence. The meta-analysis indicated that beliefs regarding the necessity of medication and concerns about medication are modifiable. Importantly, it showed that these beliefs are strongly associated with medication adherence. Specific behavior change techniques that led to a significant change in medication belief were identified. These findings advance the field of medication adherence highlighting which techniques are most likely to be effective.

This article was published Online First October 23, 2023.

Elizabeth Sheils  <https://orcid.org/0000-0003-4499-3166>

The research protocol was registered with the International Prospective Register of Systematic Review on June 18, 2018 (Registration: CRD42018093966). The protocol was updated when searches were updated in 2020 and it was apparent a meta-analysis was feasible. This study was part of a PhD funded by the University of Bath's "University Research Studentship Award." Ethical approval was not required for this research. The authors have no conflicts of interest to disclose. We would like to thank Emily Rickard for insightful discussion, comments, and suggestions on drafts of the article.

Elizabeth Sheils served as lead for data curation, formal analysis, investigation, methodology, project administration, writing—original draft, and writing—review and editing. Sarah C. E. Chapman served as lead for funding acquisition and supervision. Elizabeth Sheils and Sarah C. E. Chapman

contributed equally to conceptualization. William Tillet, Delyth James, Sarah Brown, Charlotte Dack, Hannah Family, and Sarah C. E. Chapman contributed equally to investigation, methodology, writing—review and editing, and formal analysis. William Tillet, Delyth James, Charlotte Dack, and Hannah Family contributed equally to supervision.

Open Access funding provided by the University of Bath: This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0; <https://creativecommons.org/licenses/by/4.0>). This license permits copying and redistributing the work in any medium or format, as well as adapting the material for any purpose, even commercially.

Correspondence concerning this article should be addressed to Elizabeth Sheils, Department of Life Sciences: Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom. Email: elizabeth.sheils@bath.edu

Keywords: attitudes, behavior change techniques, medication adherence, systematic review, meta-analysis

Supplemental materials: <https://doi.org/10.1037/hea0001316.supp>

Patients hold a plethora of beliefs about medication, going beyond a simple evaluation of efficacy and adverse effects and incorporating rich perceptions of the treatment in relation to themselves and the treatment context (Horne et al., 2019). Beliefs about prescribed medication are related to medication behaviors such as adherence (taking medication as prescribed; European Patients Forum, 2015) across a wide range of conditions (Horne et al., 2013) and can influence understanding of medication effects, for example, inducing negative expectations that affect experiences of side effects via nocebo effects (Heller et al., 2017) and predicting misattribution of symptoms as side effects of medication (Heller et al., 2015). Beliefs are integral to who we are and what we do, and can be distinguished from knowledge, as they do not necessitate objective truth (Connors & Halligan, 2015). Regardless of objective truth, beliefs are held with conviction, regarded as true, and provide a framework for behavior and understanding (Halligan & Aylward, 2006). Models such as the Necessity-Concerns Framework (Horne et al., 2013) and the Common-Sense or Self-Regulatory Model (Hagger & Orbell, 2022) propose that medication beliefs can influence responses to illness for example, engaging with healthcare and adhering to treatment if medications are perceived as effective and safe. Rates of long-term conditions (Department of Health and Social Care, 2012) managed using prescribed medication (NHS, 2017; Simpson et al., 2006) are increasing meaning it has become imperative to better understand and, where appropriate, change patients' medication-related beliefs.

Medication beliefs can be drawn from a wide range of sources including direct experience with treatment, observations of other people's experiences or information from diverse sources such as healthcare professionals (HCPs) and social media (Al Khaja et al., 2018). Linn et al. (2019) found that online information seeking was associated with greater concerns about medication and patients who sought information after consultation were found to be more nonadherent at 3 weeks compared to those who did not. Patients' medication-related beliefs are intrinsically subjective and often differ from the views of HCPs (Mårdby, 2008). Patients' beliefs regarding treatment can often be categorized into two main groups. These groups are based on their perceived need for treatment (referred to as "necessity beliefs") with the anticipated benefits (e.g., prevention of disease progression), and their concern about the potential negative outcomes of taking medication (known as "concern beliefs," e.g., dependency, potential adverse effects; Horne, 1997; Horne et al., 1999, 2013; Horne & Weinman, 1999). They can also include the likelihood that the medication can cure or control disease (Leventhal et al., 2003). Medication beliefs can also encompass general themes such as the nature of pharmaceuticals and whether they are overused (Horne & Weinman, 1999), beliefs about the manufacture of medications, efficacy of generic versus branded medication (Colgan et al., 2015; Keenum et al., 2012), and the trustworthiness of the pharmaceutical industry (Goff et al., 2008). Beliefs can also involve broader domains such as cultural beliefs and beliefs related to one's control over the disease.

The most extensively researched effect of medication-related beliefs is adherence. Treatment adherence is highly variable ranging from 0% to over 100% (Nieuwlaat et al., 2014). Overall, an estimated 30%–50% of patients are nonadherent (Brown & Bussell,

2011; Osterberg & Blaschke, 2005; Sabaté, 2003). Three meta-analyses have indicated stronger beliefs about the necessity of medication and fewer concerns about its potential negative effects are associated with greater adherence (Foot et al., 2016; Horne et al., 2013; Nie et al., 2019). While some nonadherence is unintentional (patients don't adhere due to reasons outside of their control), it is frequently intentional (deciding not to adhere often because of medication-related beliefs; Nunes et al., 2009). A recent systematic review (Shahin et al., 2019) found a statistically significant association between personal and cultural beliefs and medication adherence. Gonzalez et al. (2015) demonstrated through mediation analysis a significant indirect effect on diabetes distress and medication adherence through perceived control of the condition. While some nonadherence may have positive effects (e.g., by reducing adverse effects), it can lead to suboptimal therapeutic management (Cramer et al., 2008; DiMatteo et al., 2002), lost health gains, exacerbated symptoms, increased morbidity (Jimmy & Jose, 2011; Simpson et al., 2006), and financial burdens on healthcare systems (Cutler et al., 2018). It has been argued that above any other intervention, improving adherence creates more health gains (Sabaté, 2003); however, minimal improvement has been noted in adherence across the last 50 years (Nieuwlaat et al., 2014). Although we may be unable to cure conditions we have significant advances in treatment, thus finding ways to improve beliefs about medication is imperative to the treatment pathway.

It may be possible to modify patients' medication-related beliefs, supporting adherence, and other health outcomes. For example, pharmacist counseling of cancer patients decreased medication concerns, increased necessity beliefs, and increased adherence (Birand et al., 2019). Likewise, tailored text messages reduced medication concerns and increased adherence in patients with inflammatory bowel disease (Riaz & Nielsen, 2019). In addition, several randomized controlled trials (RCTs) that have aimed to change medication-related beliefs found a significant change between the intervention and the control group postintervention, including an individualized integrative nursing intervention for people with schizophrenia (Dahan et al., 2016), a relapse prevention program for depression (Lin et al., 2003), and a targeted text message intervention for asthma patients (Petrie et al., 2012). These three interventions also noted an improvement in adherence for the intervention group. To our knowledge, no systematic review has summarized evidence on the effectiveness of interventions to modify medication-related beliefs in RCTs.

The current systematic literature review and meta-analysis aims to: (a) identify which techniques are used within interventions which measure medication-related beliefs; (b) test the effectiveness of these interventions in changing medication-related beliefs using meta-analysis; (c) test whether the presence of specific intervention techniques moderate the effectiveness of interventions; and (d) assess the quality of reporting and risk of bias of included studies.

Method

See online supplemental material 1 for preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement.

International Prospective Register of Systematic Review Registration Number CRD42018093966. The systematic review was originally conducted in July 2018 and updated in November 2020, with the addition of meta-analyses. The review process was conducted over an 18-month period.

Inclusion/Exclusion Criteria

Participants: Adults (aged 18 years old and older) prescribed medication for one or more long term conditions (typically lasting a year or longer). **Interventions:** Any method except those focused on modification of patients' medication (e.g., titrating dose), targeting patients and/or HCPs, and taking place in any setting or geographical location. **Comparison:** Usual care or other control. **Outcomes:** Medication-related beliefs assessed postintervention. **Study design:** RCTs.

Literature Search

We searched CBI Medline, Embase, APA PsycINFO and PsycARTICLES, ProQuest, and Cochrane Library, from the earliest available date to November 20, 2020. Reference lists of included studies were screened to identify additional relevant articles. We explored "grey" literature such as conference presentations and theses. The search included terms relating to participants, intervention, outcome, and study design (see [online supplemental material 2](#) for full description of search). We searched for words/phrases and used index terms such as MeSH and combined terms with Boolean logic. We identified online supplemental materials/web-sites and contacted authors for documents as needed.

Study Selection

We identified 13,540 results, of which 3,713 were duplicates. We removed 9,691 results during title/abstract screening, and 80 after full text screening, leaving 56 papers included. See [Figure 1](#) for PRISMA diagram. Studies were independently screened by two reviewers (Elizabeth Sheils and Sarah C. E. Chapman) with high agreement (Cohen's $k = 99\%$). Disagreements were resolved by consensus.

Data Extraction

Data were extracted into Excel. Data extracted included the study aim and design, patient diagnosis/es and medication details, setting, country, sample characteristics, intervention and control characteristics, measure of medication-related beliefs and belief effect size, measure of adherence and effect size, follow-up duration, risk of bias, and intervention description quality.

Identification of Techniques Included in the Intervention/Control Conditions

We used the behavior change technique taxonomy v1 (BCTT; [Michie et al., 2013](#)) as the primary method to code techniques included within the interventions. A behavior change technique (BCT) has been described as the smallest component with the potential for behavior change which is replicable and observable ([Michie et al., 2013](#)). The BCTT, including 93 BCTs clustered in 16 domains, has been used to evaluate interventions across health domains including physical activity ([Samdal et al., 2017](#)), smoking

cessation ([Bartlett et al., 2014](#)), and medication adherence smart-phone applications ([Morrissey et al., 2016](#)). We selected it for this study because many of the terms used to describe interventions are used inconsistently, for example "pharmacist counseling" could involve didactic information provision or asking patients to share their thoughts whereas the BCTs are clearly defined. A program of work involving expert consensus exercises and systematic reviews has mapped BCTs to potential mechanisms of action including belief change. For example, the BCT "information about health consequences" is thought to affect behavior in part through modifying beliefs about the consequences of a behavior and perceptions of susceptibility to negative consequences ([Carey et al., 2019](#); [Connell et al., 2019](#)). Although most of our studies were likely to consider medication-related beliefs linked to medication behaviors, making the BCTT relevant, there might be some studies which included techniques to change beliefs without the goal of changing behavior, and so we included a section on our data extraction form to record these.

To ensure accurate coding, coders completed training (BCT Taxonomy v1: Training, n.d.), checked codes against previous coding by other researchers (BCT Taxonomy v1: Interventions, 2018), examined available additional sources (e.g., protocols) for further details, built a coding manual with examples of BCTs (see [online supplemental material 3](#)), and extracted supporting evidence from text while coding. Following previous studies ([Newby et al., 2021](#); [Peters et al., 2015](#)) only BCTs described in the intervention but not the control condition were coded. BCT coding took place in August–October 2020 and November–December 2020 following rerunning and updating the searches.

Risk of Bias

Cochrane's Risk of Bias tool (RoB 2; [Sterne et al., 2019](#)), was used to evaluate potential risk of bias in: randomization, fidelity, missing data, outcome measurement, and selective reporting. Each item was coded as: (possibly) yes/(possibly) no/not applicable/no information. An algorithm was used to make overall risk-of-bias judgements.


Quality of Intervention Description

The "template for intervention description and replication" (TiDiR; [Hoffmann et al., 2014](#)) was used to assess reporting quality ([de Barra et al., 2019](#); [MacDonald et al., 2016](#)). It includes 12 items covering intervention name, rationale, materials and procedures, who provided, location, mode of delivery, when and how much, tailoring, modifications, and fidelity. Each item was coded as: adequately/inadequately/not reported or not applicable.

Coding Checks

All data were extracted by one reviewer (Elizabeth Sheils) and discussed with a second reviewer (Sarah C. E. Chapman). A random sample of 10% of studies were independently coded by a second reviewer (Sarah Brown) using RoB2 and TiDiR. There was a high rate of interrater reliability 70.8% for TiDiR and 84.0% for RoB2 with disagreement focused on coding of "not reported" versus "not applicable." Two coders (Elizabeth Sheils and Sarah Brown) coded all BCTs independently but met weekly to discuss and resolve disagreements, with input from the full team as needed. The

Figure 1
PRISMA Flow Chart



Note. PRISMA = preferred reporting items for systematic reviews and meta-analyses.

reviewers agreed about the presence of a BCT independently on 57.7% of occasions, and resolved the remainder of instances through discussion.

Meta-Analysis

Meta-analysis was performed in Stata 17. Studies were included studies in the meta-analysis if effect sizes on medication-related beliefs could be computed. Medication-related beliefs were grouped into those concerning perceived need for medication (e.g., Beliefs About Medication questionnaire [BMQ]-Necessity, Drug Attitude Inventory [DAI]) and perceived negative effects of medication (e.g., BMQ-Concern). A random-effects model was used to estimate effect sizes, given that we expected true effect sizes to be heterogeneous across different patient groups and interventions (Hunter & Schmidt, 2000). Hedges' g was used for effect sizes because of the presence of some studies with small samples (Hedges & Olkin, 1984). We conducted moderator analyses to examine whether effect sizes were larger for studies with versus without identified BCTs. We tested for heterogeneity using Q statistics and expressed the percentage of variation due to heterogeneity rather than chance using the I^2 statistic (50%–90%

represents substantial heterogeneity; Deeks et al., 2019). Publication bias was assessed by examining funnel plot asymmetry and the Trim and Fill method (Thornton & Lee, 2000) and Egger's test for small study bias (Egger et al., 1997). Sensitivity analyses were performed by excluding studies with high risk of bias and exploring the outcome measures. Subgroup analyses by examining the studies which had measured and found significance in adherence for the intervention group versus control postintervention.

Results

Study and Participant Characteristics

There were 56 included studies (8,714 randomized participants, data reported on 7,730). They were conducted across four continents Europe ($n = 28$), Asia ($n = 12$), North America ($n = 9$), and Australia/Oceania ($n = 7$). Median publication year was 2013 (range 1982–2020). Four studies reported multiple intervention groups (two in Krasnoryadtseva et al., 2020; Linn et al., 2018; Polack et al., 2008, three in Mazor et al., 2007). Linn et al. (2018) also reported on two control groups. Therefore, 61 intervention

and 57 control groups were identified. The average age of participants was 51.7 years in the intervention and 52.2 years in the control groups. Most studies had an equal number of males and females, average 46.5% female participants (range 0%–100%). Most samples ($n = 31$) had physical health conditions, 22 had mental health conditions, and three had comorbid physical and mental health conditions. See Table 1 and online supplemental material 4 for full details of the studies.

Intervention Characteristics

There was a wide range of interventions. The most common were: a combination of education, support, problem solving, medication reviews, and referral (delivered in 12 interventions); “adherence therapy,” a manualized therapy combining principles of

motivational interviewing and cognitive behavioral therapy (Gray et al., 2006) delivered in 11 interventions via between three weekly sessions to 14 sessions across 6 months; tailored problem solving (11 interventions); pharmacist consultations with/without follow-up via HCP or text message (seven interventions); and education/psychoeducation (six interventions). Five studies provided tailored visual and/or written information. Three studies used motivational interviewing (between three and seven sessions). Interventions were most frequently delivered by a pharmacist ($n = 18$).

Control Conditions

Forty-four control groups received usual care, 12 control groups received an active control (e.g., basic education). One paper did not describe the control condition.

Medication-Related Belief Measure

The majority of studies ($n = 33$) used a form of the BMQ (Horne et al., 1999) to measure beliefs, while 14 studies used the DAI (Hogan et al., 1983), which explores similar components to the BMQ.

Primary Outcome

The most common primary outcome was medication adherence ($n = 30$).

Medication Adherence

Forty-three studies measured medication adherence with 23 reporting a significant increase in adherence, one study reported significant increase in adherence at 6-month follow-up but not 12 months (Clarksmyth et al., 2013), 18 reporting nonsignificance, and one study excluding results due to ceiling effects (Uzenoff et al., 2008).

BCTs

A total of 251 BCTs were coded from 53 study reports. One study had no unique BCTs in the intervention group compared with the control (Krasnoryadtseva et al., 2020) and two studies had insufficient information (Adams et al., 2015; Prasetya et al., 2018). The mean number of BCTs in interventions was 4.74 (SD 2.98, range 1–14). See Figure 2 for frequency of BCTs. Of the 93 possible BCTs, 34 were identified from 14 of the 16 domains (all except scheduled consequences and covert learning) indicating the breadth of techniques used. The most common BCTs were “problem solving” (in 34 interventions), “information about health consequences” (in 28 interventions), and “social support (unspecified)” (in 27 interventions). The BCTs were operationalized in a wide variety of ways, for example, information about health consequences was provided via leaflets, videos, and face-to-face while social support (unspecified) was delivered via cognitive-behavior therapy, and support from family and friends (see Table 2 for definitions and examples). Many BCTs were used by very few studies, for example, eight BCTs used only once: goal setting (outcome), discrepancy between current behavior and goal, review outcome goals, behavioral contract, commitment, feedback on behavior, habit formation, and social reward. Ten of 11 studies which had belief/attitude as the primary outcome measure had codable


Table 1

Intervention Group Details and Outcome Measures ($n = 56$)

Component	<i>n</i>
Intervention lead	
Pharmacist	18
Technology	9
Researcher	8
Nurse	7
Psychologist	3
Psychiatrist	3
Other	8
Delivery mode	
Face-to-face individual	35
Electronic device (app/text)	16
Face-to-face group	5
Setting	
Hospital outpatient clinic	14
Pharmacy	11
Inpatient	8
Mobile (text message/app/voice message)	7
GP/academic setting	5
Telephone	5
Home	2
Prison	2
Not specified	2
Primary outcome	
Adherence/compliance	30
Belief/attitude	11
Symptoms/quality of life	6
Knowledge	4
Other	5
Belief measure(s)	
BMQ-specific (Horne et al., 1999)	27
BMQ-general (Horne et al., 1999)	14
Two questions from BMQ	4
Drug Attitude Inventory (Hogan et al., 1983)	14
Antidepressant belief measure	3
Other	6
Adherence measure	
Morisky Medication Adherence Scale (Morisky et al., 1986)	7
Medication Adherence Report Scale (Horne & Hankins, 2008)	5
Medication Adherence Rating Scale (Thompson et al., 2000)	4
Dispensing records	4
Physiological	4
Interview	3
Medicine Adherence Questionnaire	3
Other/unspecified self-report	13

Note. GP = general practitioner; BMQ = Beliefs about medicines questionnaire.

Figure 2
Number of Interventions Containing Each BCT



Note. BCT = behavior change technique.

BCTs (range 2–7 BCTs) with the most prevalent BCT being “social support (unspecified)” (eight interventions) followed by “problem solving” (seven interventions).

Quality of Description

The TIDieR checklist highlighted some aspects of interventions that were well reported (e.g., brief name and rationale were both reported by all studies and “who provided” the intervention was adequately reported in 84% of studies). Other aspects were less well described for example, 46% provided a detailed description of intervention materials, 7% reported modifications, and 30% reported fidelity (see Figure 3).

Risk of Bias

Overall, most studies had “some concerns” of bias, $n = 49$, and seven studies were “high risk” (see Figure 4). Most studies ($n = 48$) had low risk of bias for “randomization” and “deviation from intended interventions” ($n = 54$). The main sources of potential bias across all studies was “measurement outcome,” primarily due to reliance on self-report outcomes (inevitable for studies exploring medication-related beliefs) in all studies, and that protocols were obtainable for only 10 studies making it difficult to assess if only a selection of outcomes were reported.

Intervention Effects on Medication-Related Beliefs

Meta-Analysis Results

We included 36 of the 56 studies in the meta-analysis, with 20 studies providing insufficient data to enable calculation of one or more effect sizes. Interventions were had a small-to-medium statistically significant effect on beliefs about medication need/benefit ($n = 36$), $g = .362$, $p < .001$, 95% confidence interval (CI) [0.204, 0.521], and small-to-medium statistically significant effect on concerns about medication ($n = 21$) $g = -.435$, $p < .01$, 95% CI [-0.721, -0.149]. There was high heterogeneity around both medication need, $Q(35) = 226.50$, $I^2 = 84.74$, and concerns estimates, $Q(20) = 246.31$, $p < .001$, $I^2 = 91.27$. See [online supplemental material 5](#) for forest plots.

Sensitivity Analyses

To ensure the results were not driven by potential outliers, leave-one-out meta-analysis was conducted and revealed no single study had a dramatic impact on the overall model (overall model Hedges' g ranged from .311 to .382 for necessity and -.474 to -.36 for concerns). Next, we repeated the analyses with the studies at “high risk of bias” removed with minimal impacts on effect sizes or heterogeneity (necessity analysis: $n = 33$, Hedges' $g = .356$, $p < .001$, 95% CI [0.182, 0.531], $I^2 = 85.59$; concerns analysis: $n = 20$, Hedges' $g = -.429$, $p < .01$, 95% CI [-0.730, -0.129], $I^2 = 91.89$).

Table 2*Three Most Frequently Coded BCTs With Examples*

BCT	Definition from BCT taxonomy (Michie et al., 2013)	Example of BCT in included study
1.2 Problem solving	Analyze, or prompt the person to analyze, factors influencing the behavior and generate or select strategies that include overcoming barriers and/or increasing facilitators	"Patients were helped to identify obstacles that might prevent them from taking medication, to identify strategies to overcome obstacles that arise, and to build self-efficacy." (Pakpour et al., 2017)
3.1 Social support (unspecified)	Advise on, arrange, or provide social support (e.g., from friends, relatives, colleagues, buddies, or staff) or noncontingent praise or reward for performance of the behavior.	"Counseling to cope with lack of motivation will focus on exploring the patients' concerns and necessity beliefs. This method is called motivational interviewing." (Alfian et al., 2021)
5.1 Information about health consequences	Provide information (e.g., written, verbal, visual) about health consequences of performing the behavior	"The research fellow also provided information on the likelihood of experiencing any side effects mentioned." (O'Carroll et al., 2013)

Note. BCT = behavior change technique.

Sensitivity analysis was also conducted to investigate whether the outcome measure influenced the results. When the BMQ-Necessity outcome was removed, 17 studies remained, Hedges' $g = .307$, $p < .001$, 95% CI [0.228, 0.386], $I^2 = 0$. When the DAI outcome was removed, 26 studies remained, Hedges' $g = .387$, $p < .01$, 95% CI [0.176, 0.599], $I^2 = 87.76$. When other outcome measures were removed (retaining the most frequently used measures, BMQ and DAI), 29 studies remained. Hedges' $g = .366$, $p < .001$, 95% CI [0.172, 0.561], $I^2 = 87.21$. The results were similar, suggesting no significant difference in the psychometric measures.

Publication Bias

Publication bias analysis was mixed. For necessity beliefs, while Egger's statistic was nonsignificant suggesting no publication bias, $t(36) = -0.02$, $p = .99$, 95% CI [-1.79, 1.76], trim and fill analysis imputed 11 studies to the right of the mean, increasing the overall effect size ($g = .555$, 95% CI [0.397, 0.713]). Similarly for concern beliefs, Egger's statistic was also nonsignificant suggesting no publication bias, $t(21) = 1.09$, $p = .29$, 95% CI [-1.34, 4.23], whereas trim and fill analysis imputed four studies to the left of the mean, $g = -.581$ (95% CI [-0.863, -0.299]) (see [online supplemental material 6](#) for funnel plots).

Subgroup Analysis—Adherence

Studies which reported a significant improvement in adherence for the intervention group ($n = 16$) had larger effects on beliefs for necessity ($g = .48$, $p < .001$, 95% CI [0.25, 0.71]), $Q(15) = 146.22$, $I^2 = 88.32$, relative to those that did not ($n = 11$, $g = .04$, $p = .104$, 95% CI [-0.15, 0.22]), $Q(10) = 15.85$, $I^2 = 30.77$. The difference between the two groups was significant, $Q(1) = 9.95$, $p < .001$. Similarly, where there was a significant improvement in adherence in the intervention group there was a larger reduction in concerns ($n = 10$, $g = -.52$, $p < .001$, 95% CI [-0.99, -0.5]), $Q(9) = 168.14$, $I^2 = 92.38$, than when there was no significant difference in adherence ($n = 6$, $g = -.04$, $p = .237$, 95% CI [-0.31, 0.24]), $Q(5) = 6.79$, $I^2 = 1.69$. The difference between these two groups was significant, $Q(1) = 4.82$, $p < .05$.

Moderator Analysis—BCTs


Moderator analyses were conducted for the 33 studies in which BCTs were coded to test for the univariate effect of individual

BCTs on beliefs. Fourteen BCTs were associated with significant increases in medication need beliefs (goal setting, action planning, social support [unspecified], social support [practical], information about health consequences, social comparison, pros and cons, comparative imagining future outcomes). The largest effect sizes were seen for interventions including comparative imagining future outcomes ($g = .610$), goal setting behavior ($g = .531$), and action planning ($g = .541$). Four BCTs were associated with a significant reduction in concern/worry beliefs related to medication: action planning ($g = -.679$), problem solving ($g = -.498$), social support (unspecified; $g = -.571$), and information about health consequences ($g = -.510$). Of the BCTs identified, two were associated with nonsignificant increases in medication need beliefs, credible source and incompatible beliefs. Five BCTs were associated with a nonsignificant reduction in concern/worry beliefs related to medication: framing and reframing, social support (practical), salience of consequences, prompts and cues, and credible source. Only one BCT, credible source, was found to be nonsignificant for both necessity and concern beliefs. Interventions did not have significantly larger effects when including any individual BCT than without it (nearly all comparisons between interventions including a BCT vs. interventions not including it were nonsignificant [all p values $> .05$]; see [Figure 5](#)).

Discussion

This systematic review and meta-analysis identified RCTs which measured medication-related beliefs and assessed BCTs within interventions that measured medication-related beliefs in individuals prescribed medication/s for a chronic health condition. We found a heterogeneous set of interventions which had been offered to a wide variety of patient groups across different settings. Meta-analysis revealed a small-to-medium effect of the interventions on both need and concern/worry medication-related beliefs. A wide variety of BCTs were identified within the interventions with the most common being providing information about health consequences, problem solving, and social support (unspecified). These effects were larger for studies that reported that the intervention improved adherence. Interventions including these three BCTs significantly increased necessity beliefs and reduced concerns. These three BCTs were amongst the most prevalent in a recent meta-analysis exploring telecommunication interventions aimed at promoting adherence to cardiometabolic medication (Kassavou & Sutton, 2018). There was

Figure 3
Summary of TIDieR Checklist for Included Studies ($n = 56$)



Note. TIDieR = template for intervention description and replication.

some evidence that “credible source” was not associated with significant changes in either necessity or concern beliefs. However, including any individual BCT did not result in a significantly larger effect on medication-related beliefs relative to interventions without these BCTs. There was evidence of potential gaps in intervention reporting, bias in study design, and publication bias.

To our knowledge this is the first systematic review and meta-analysis to use the behavior change taxonomy to synthesize RCTs measuring of medicated-related beliefs. A wide range of physical and mental health conditions were included, with an equally broad range of interventions. Similar to previous reviews focusing on improving adherence (Horne et al., 2019; Nieuwlaat et al., 2014) the included studies were largely heterogeneous with differences in condition, intervention, timescales, and medication, thus making it challenging to reach definitive conclusions.

What Techniques Are Used in Interventions Which Measured Medication-Related Beliefs?

Rather than looking at groups of interventions, this study’s first aim was to identify the active components of the interventions using the BCTT (Michie et al., 2013). Both the interventions with a primary outcome related to a specific behavior, for example, adherence, as well as interventions that had beliefs/attitudes as the primary outcome were captured by the BCTT. A range of BCTs were identified. Of the 93 possible BCTs, 36.6% were identified amongst the included studies covering 87.5% of the taxonomy domains. The top five coded BCTs were problem solving, information about health consequences, social support (unspecified), credible source, and pros and cons. Problem solving and pros and cons were operationalized similarly across studies, frequently “structured” or “guided” where individuals looked at medication problems or cons and then discussed potential solutions or pros. Information about health consequences, social support (unspecified), and credible


source were all operationalized differently. Information and support were provided in several different ways and the term credible source captured a number of different HCPs.

There may be “untapped” potential in a range of BCTs which were not included in many interventions or identified as included in very few interventions in the current review. While many of these may not be relevant to medication-related beliefs and behaviors, there are certainly some which were not identified which might be interesting candidates for future intervention research. Many of the untested BCTs would be predicted by theory to be potentially effective in changing medication beliefs. For example, biofeedback, where feedback about the body is provided using an external monitoring device was not identified in any interventions but would seem relevant for addressing doubts about medication efficacy for example, address doubts that antihypertensive medications are affecting blood pressure (McManus et al., 2018). Reattribution was also untested despite theories pointing to the role of misattribution of symptoms as adverse effects in increasing their medication concerns (Petrie & Rief, 2019). Anticipated regret around the consequences of not taking medication was unused, although it has been found to motivate uptake of Human Papillomavirus vaccination (Caso et al., 2019) and taking the contraceptive pill (Molloy et al., 2012). Other BCTs commonly used and known to be effective in interventions focused on changing beliefs linked to behaviors such as cognitive behavioral therapy (Bennett-Levy et al., 2004), for example, behavioral experiments were also not identified in any of the included studies. Future research exploring a broader range of BCTs may identify techniques which could increase the effect of interventions on medication beliefs.

How Effective Were Interventions in Changing Medication-Related Beliefs?

Our meta-analyses found that interventions had significant small-to-moderate effects on perceived need for treatment and concerns relative to control groups. Small-to-moderate effects may be

Figure 4
Risk of Bias v2 Assessment (n = 56)



expected to have meaningful clinical impacts on patients. In the current review, studies which were effective for changing medication-related beliefs, the majority noted an improvement in adherence. However, it is unclear whether outcomes that might be viewed as the most important by patients and clinicians (for example, reductions in mortality, complications, and hospitalizations) would be achieved by these interventions given that the beliefs have small-to-moderate effects on behaviors, which, in turn, have small effects on clinical outcomes. Given these relatively small effect sizes, there is potentially a need for more effective methods to modify beliefs and maximize benefits to patients. This is particularly true given the intensive nature of some of the interventions, requiring high levels of commitment and time from both patients and HCPs. The costs of providing these interventions may therefore need to be balanced against their benefits in clinical practice.

Do Specific Techniques Increase the Effectiveness of Interventions?

The three most prevalent effective BCTs were problem solving, information about health consequences, and social support (unspecified). The most frequent BCT was problem solving. Problem solving was mainly operationalized in the included studies by providing participants with “structured problem solving” (identifying barriers and facilitators to taking medication). On first look, it is surprising that this BCT was the most frequent in effective interventions which changed medication beliefs given that it is usually thought of as addressing practical barriers to medication-taking rather than perceptual. Possibly, participants who undertook problem solving addressed barriers and facilitators that impacted on their beliefs, for example, a patient may have explored ways of better coping with adverse effects and therefore reduced their medication concerns. Alternatively, problem solving was always delivered in combination with other BCTs so these other codelivered BCTs may have contributed to this effect.


Providing information about health consequences was the next most common effective BCT, this may be an important tool in educating patients about the role of medication in their long-term condition. Previous literature has highlighted that individuals with higher concern beliefs and lower necessity are less likely to adhere (Foot et al., 2016; Horne et al., 2013) and more likely to misattribute symptoms as side effects of medication (Heller et al., 2015). Thus, being provided with information about health consequences of taking versus not taking medication may directly address certain medication-related beliefs.

The third most prevalent BCT was social support (unspecified) which was provided in a range of methods including counseling, a free telephone support line, and cognitive behavioral therapy. Therapies which frequently involve changing beliefs, for example cognitive-behavioral therapy to explore depressive thinking patterns, are grounded in a supportive setting. Results from 16 meta-analyses exploring psychotherapy outcomes, concluded that the therapeutic relationship was as important, if not more so, than the treatment method itself (Norcross & Lambert, 2018). An increasing literature also speaks to the importance of trust for medication-related beliefs. With research suggesting, a patient’s trust in their doctor improved knowledge about medication and adherence (AlRuthia et al., 2019). Perhaps interventions where participants received support resulted in greater trust in healthcare systems and medication and therefore influenced medication beliefs.

The three aforementioned BCTs can be operationalized in different ways which is advantageous given the range in healthcare resources throughout the world and the variability in patients preferences, for example, support could be provided via telephone or face-to-face counseling.

Only one BCT, credible source ($n = 13$), was found to be in more “noneffective” studies for both necessity and concern beliefs. A wide range of interventions were utilized amongst these thirteen studies. One potential difference noticed amongst the studies was training; 60% of the “effective” studies involved training (manuals

Figure 5
Hedges' *g* for BCTs



Note. BCT = behavior change technique.

and face-to-face training, with some studies mentioning training in communication). Whereas only 38% of “noneffective” studies mentioned specific training. A growing evidence base suggests that the interaction and relationship with a credible source (or physician) can influence health outcomes. Cross-sectional research found the quality of physician–doctor relationship influenced treatment recommendation adherence, with individuals reporting better relationships with their physician perceiving treatment recommendations as more influential (Orom et al., 2018). Therefore, credentials of a credible source may be insufficient alone to change medication-related beliefs.

Quality of Reporting, Risk of Bias, and Publication Bias

All included studies had either some concern or high risk of bias, this was expected due to the nature of the interventions. However, sensitivity analysis in the meta-analysis suggested the studies rated as “high risk of bias” did not have an impact on the overall findings. Within behavioral interventions blinding is not possible since it was clear whether a participant was receiving the intervention or control and the outcome was assessed using self-report, leading to the studies being rated as having “some concerns.” Few studies reported on the fidelity of intervention delivery adequately, meaning that interventions may have been modified when delivered. Additionally, interventions and control conditions were often inadequately described. While all papers had some details of their interventions, the exact content of the materials (such as medication review script) was unavailable, and so the active components may not be correctly,

or fully, identified (Hoffmann et al., 2014; Horne et al., 2005). The results of the publication bias test were mixed: Egger’s test for small study bias was nonsignificant suggesting no publication bias, however Trim and Fill methods imputed several studies, increasing the overall estimated effect size. The high levels of heterogeneity (I^2) may cause funnel plot asymmetry despite absence of bias (Terrin et al., 2003). The systematic relationships between study precision and effect size may underpin the heterogeneity (Ioannidis & Trikalinos, 2007), for example if reporting of clinical outcomes/adherence was prioritized over belief outcomes. However, this is highly speculative and evaluation of publication bias can only be performed by comparing published literature to a robust trial register.

Strengths and Limitations

The review was conducted systematically, and a robust approach was adopted, adhering to the latest PRISMA guidance. A second coder was used for a proportion of studies to assess bias and quality, to maximize rigor. This is the first systematic review and meta-analysis of its kind to examine intervention content using the BCT taxonomy to identify effective interventions measuring medication-related beliefs. Additionally, bias related to interpreting the BCTv1 taxonomy were minimized by having two researchers independently extract available BCTs from all 56 included papers and meet to discuss interpretations. There are limitations to this review, data were extracted by one researcher. However significant effort was taken to ensure the accuracy of the data by the study team overseeing

data extraction, discussing effect size calculations, and returning to the dataset at a different timepoint to check. There were also limitations arising from reporting quality and potential publication bias meaning that our findings might not accurately represent the full range of interventions tested. The underreporting of active ingredients is a significant challenge to behavioral research synthesis (de Bruin et al., 2021). Finally, the search was conducted in November 2020 and keyword searches in PubMed found approximately six potentially relevant articles for inclusion from that date. However it is unlikely that all would have sufficient information for BCT coding or meta-analysis. It is possible that reports may change the results for some of the BCTs which have been less tested, but it is unlikely that the findings would change for the most frequently identified BCTs. An updated review would benefit from utilizing the latest behavior change taxonomy, outlined below in future research.

Future Research

Future research would benefit from identifying how to maximize the effectiveness of interventions. For example, interviewing patients and HCPs to understand the best ways of operationalizing BCTs within their specific health condition. Additionally, future research could examine which BCTs work for which medication-related beliefs, to enable brief personalized intervention development, explore some of the undertested techniques, and explore whether BCTs work best in combination or whether they are sufficient by themselves. Furthermore, with the advent of the behavior change intervention ontology (Marques et al., 2023), a new dawn arises in our capacity to develop shared understanding of behavior change theories, intervention techniques, target behaviors, and contextual factors that influence behavior change. Training materials in how to code according to this revised framework are yet to be released, once these are available a new systematic review and meta-analysis could apply the ontology to medication-related beliefs.

Implications for Practice

The current review addresses beliefs about medications and informs the field about change in those beliefs. Meta-analysis indicates that beliefs regarding the necessity and concerns about medication are modifiable. Importantly, the beliefs are strongly associated with medication adherence. Specific BCTs associated with medication-related change are identified. There was strongest evidence for the importance of problem solving, information about health consequences, and social support (unspecified), in changing medication beliefs. Those looking to design adherence interventions that change medication-related beliefs could explore these BCTs. There are numerous ways to provide problem solving, information, and social support. Interventionists could interview patients and HCP in specific health conditions to investigate the best method to utilize the BCTs within the health condition and resources. We found that many BCTs had not been included, suggesting there may be untapped potential. Interviews could therefore also provide an opportunity for patients and HCPs to explain “what else” is important for medication-related beliefs. Outside of formal interventions, these BCTs could potentially be operationalized in routine clinical practice to support patients. Given the importance of medication beliefs for adherence, perceptions of adverse effects, and

satisfaction with treatment, more empirical research testing interventions specifically focused on beliefs may benefit patients and the HCPs who treat them.

Resumen

Objetivo: Las creencias relacionadas con los medicamentos, por ejemplo, las creencias de que los medicamentos son innecesarios o que es probable que se produzcan efectos secundarios, pueden influir en las conductas y experiencias con los medicamentos, lo que podría afectar la calidad de vida y la mortalidad. En ocasiones, puede resultar útil cambiar las creencias relacionadas con los medicamentos, por ejemplo, para reducir las preocupaciones de los pacientes sobre los efectos secundarios cuando la evidencia extensa sugiere que los efectos secundarios son raros. Actualmente no conocemos los métodos más eficaces para abordar las creencias sobre la medicación. **Métodos:** Revisión sistemática y metaanálisis de pruebas controladas aleatorizadas que midieron las creencias relacionadas con la medicación en personas a las que se les recetaron medicamentos para afecciones a largo plazo. Extrajimos datos sobre Técnicas de Cambio de Comportamiento (BCT, por sus siglas en inglés), medidas de creencias, características del estudio y del paciente, riesgo de sesgo y calidad de la descripción. **Resultados:** Identificamos 56 pruebas que asignaron al azar a 8,714 participantes. En el metaanálisis, las intervenciones produjeron efectos de pequeños a medianos ($n = 36$, g de Hedges = .362, IC [Intervalo de Confianza] del 95% [0.20, 0.52], $p < .001$) en el aumento de las creencias sobre la necesidad/beneficio de la medicación y reducir las preocupaciones sobre la medicación ($n = 21$, g de Hedges = $-.435$, IC del 95% [-0.72 , -0.15], $p < .01$). Los tamaños del efecto fueron mayores para las intervenciones que informaron un efecto significativo sobre la adherencia. La resolución de problemas, la información sobre las consecuencias para la salud y el apoyo social (sin especificar) fueron los BCTs más prevalentes. Catorce BCTs se asociaron con efectos significativos sobre las creencias de necesidad/beneficio y cuatro BCTs se asociaron con efectos significativos sobre las creencias de preocupación. **Conclusión:** Es posible modificar las creencias relacionadas con la medicación utilizando una variedad de intervenciones y técnicas. Las investigaciones futuras deberían explorar las mejores formas de poner en práctica estos BCTs para condiciones de salud específicas para respaldar las creencias sobre la medicación y mejorar la adherencia.

References

- Adams, R. P., Barton, G., Bhattacharya, D., Grassby, P. F., Holland, R., Howe, A., Norris, N., Shepstone, L., & Wright, D. J. (2015). Supervised pharmacy student-led medication review in primary care for patients with type 2 diabetes: A randomised controlled pilot study. *BMJ Open*, 5(11), Article e009246. <https://doi.org/10.1136/bmjopen-2015-009246>
- Aho-Mustonen, K., Tiitonen, J., Repo-Tiitonen, E., Ryyänänen, O.-P., Miettinen, R., & Rätty, H. (2011). Group psychoeducation for long-term offender patients with schizophrenia: An exploratory randomised controlled trial. *Criminal Behaviour and Mental Health*, 21(3), 163–176. <https://doi.org/10.1002/cbm.788>
- Alfian, S. D., van Boven, J. F., Abdulah, R., Sukandar, H., Denig, P., & Hak, E. (2021). Effectiveness of a targeted and tailored pharmacist-led

- intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: A cluster randomised controlled trial. *British journal of clinical pharmacology*, 87(4), 2032–2042. <https://doi.org/10.1111/bcp.14610>
- Alhalaia, F., Deane, K. H. O., Nawafleh, A. H., Clark, A., & Gray, R. (2012). Adherence therapy for medication non-compliant patients with hypertension: A randomised controlled trial. *Journal of Human Hypertension*, 26(2), 117–126. <https://doi.org/10.1038/jhh.2010.133>
- Ali, M., Schifano, F., Robinson, P., Phillips, G., Doherty, L., Melnick, P., & Laming, L. (2012). Impact of community pharmacy diabetes monitoring and education programme on diabetes management: A randomized controlled study. *Diabetic Medicine*, 29(9), e326–e333. <https://doi.org/10.1111/j.1464-5491.2012.03725.x>
- Aljumah, K., & Hassali, M. A. (2015). Impact of pharmacist intervention on adherence and measurable patient outcomes among depressed patients: A randomised controlled study. *BMC Psychiatry*, 15(1), Article 219. <https://doi.org/10.1186/s12888-015-0605-8>
- Al Khaja, K. A., AlKhaja, A. K., & Sequeira, R. P. (2018). Drug information, misinformation, and disinformation on social media: A content analysis study. *Journal of Public Health Policy*, 39(3), 343–357. <https://doi.org/10.1057/s41271-018-0131-2>
- AlRuthia, Y., Almalag, H., Sales, I., Albassam, A. A., Alharbi, F. A., Almutairi, A. M., Alquait, N., & Asiri, Y. (2019). The relationship between trust in primary care physicians and medication knowledge among diabetic patients. *Research in Social and Administrative Pharmacy*, 15(6), 656–661. <https://doi.org/10.1016/j.sapharm.2018.08.004>
- Appalasamy, J. R., Quek, K. F., Md Zain, A. Z., Joseph, J. P., Seeta Ramaiah, S., & Tha, K. K. (2020). An evaluation of the video narrative technique on the self-efficacy of medication understanding and use among post-stroke patients: A randomized-controlled trial. *Patient Preference and Adherence*, 14, 1979–1990. <https://doi.org/10.2147/PPA.S253918>
- Bartlett, Y. K., Sheeran, P., & Hawley, M. S. (2014). Effective behaviour change techniques in smoking cessation interventions for people with chronic obstructive pulmonary disease: A meta-analysis. *British Journal of Health Psychology*, 19(1), 181–203. <https://doi.org/10.1111/bjhp.12071>
- BCT Taxonomy v1: Interventions. (2018). *BCT Taxonomy v1: Interventions*. <https://www.bct-taxonomy.com/interventions>
- BCT Taxonomy v1: Training. (n.d.). *BCT Taxonomy v1: Training Online training*. <https://www.bct-taxonomy.com/>
- Bender, B. G., Apter, A., Bogen, D. K., Dickinson, P., Fisher, L., Wamboldt, F. S., & Westfall, J. M. (2010). Test of an interactive voice response intervention to improve adherence to controller medications in adults with asthma. *The Journal of the American Board of Family Medicine*, 23(2), 159–165. <https://doi.org/10.3122/jabfm.2010.02.090112>
- Bennett-Levy, J. E., Butler, G. E., Fennell, M. E., Hackman, A. E., Mueller, M. E., & Westbrook, D. E. (2004). *Oxford Guide to behavioural experiments in cognitive therapy*. Oxford University Press.
- Birand, N., Boşnak, A. S., Diker, Ö., Abdikarim, A., & Başgut, B. (2019). The role of the pharmacist in improving medication beliefs and adherence in cancer patients. *Journal of Oncology Pharmacy Practice*, 25(8), 1916–1926. <https://doi.org/10.1177/1078155219831377>
- Brook, O., van Hout, H., Nieuwenhuys, H., & Heerdink, E. (2003). Impact of coaching by community pharmacists on drug attitude of depressive primary care patients and acceptability to patients: A randomized controlled trial. *European Neuropsychopharmacology*, 13(1), 1–9. [https://doi.org/10.1016/s0924-977x\(02\)00074-3](https://doi.org/10.1016/s0924-977x(02)00074-3)
- Brown, M. T., & Bussell, J. K. (2011). Medication adherence: WHO cares? *Mayo Clinic Proceedings*, 86(4), 304–314. <https://doi.org/10.4065/mcp.2010.0575>
- Carey, R. N., Connell, L. E., Johnston, M., Rothman, A. J., De Bruin, M., Kelly, M. P., & Michie, S. (2019). Behavior change techniques and their mechanisms of action: A synthesis of links described in published intervention literature. *Annals of Behavioral Medicine*, 53(8), 693–707. <https://doi.org/10.1093/abm/kay078>
- Caso, D., Carfora, V., Starace, C., & Conner, M. (2019). Key factors influencing Italian mothers' intention to vaccinate sons against HPV: The influence of trust in health authorities, anticipated regret and past behaviour. *Sustainability*, 11(23), Article 6879. <https://doi.org/10.3390/su11236879>
- Cavezza, C., Aurora, M., & Ogloff, J. R. P. (2013). The effects of an adherence therapy approach in a secure forensic hospital: A randomised controlled trial. *Journal of Forensic Psychiatry & Psychology*, 24(4), 458–478. <https://doi.org/10.1080/14789949.2013.806568>
- Clarkesmith, D. E., Pattison, H. M., Lip, G. Y., & Lane, D. A. (2013). Educational intervention improves anticoagulation control in atrial fibrillation patients: The TREAT randomised trial. *PLoS ONE*, 8(9), Article e74037. <https://doi.org/10.1371/journal.pone.0074037>
- Clifford, S., Barber, N., Elliott, R., Hartley, E., & Horne, R. (2006). Patient-centred advice is effective in improving adherence to medicines. *Pharmacy World and Science*, 28(3), 165–170. <https://doi.org/10.1007/s11096-006-9026-6>
- Colgan, S., Faasse, K., Martin, L. R., Stephens, M. H., Grey, A., & Petrie, K. J. (2015). Perceptions of generic medication in the general population, doctors and pharmacists: A systematic review. *BMJ Open*, 5(12), Article e008915. <https://doi.org/10.1136/bmjopen-2015-008915>
- Connell, L. E., Carey, R. N., De Bruin, M., Rothman, A. J., Johnston, M., Kelly, M. P., & Michie, S. (2019). Links between behavior change techniques and mechanisms of action: An expert consensus study. *Annals of Behavioral Medicine*, 53(8), 708–720. <https://doi.org/10.1093/abm/kay082>
- Connors, M. H., & Halligan, P. W. (2015). A cognitive account of belief: A tentative road map. *Frontiers in Psychology*, 5, Article 1588. <https://doi.org/10.3389/fpsyg.2014.01588>
- Cramer, J., Benedict, A., Muszbek, N., Keskinaslan, A., & Khan, Z. (2008). The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review. *International Journal of Clinical Practice*, 62(1), 76–87. <https://doi.org/10.1111/j.1742-1241.2007.01630.x>
- Crockett, J., Taylor, S., Grabham, A., & Stanford, P. (2006). Patient outcomes following an intervention involving community pharmacists in the management of depression. *Australian Journal of Rural Health*, 14(6), 263–269. <https://doi.org/10.1111/j.1440-1584.2006.00827.x>
- Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018). Economic impact of medication non-adherence by disease groups: A systematic review. *BMJ Open*, 8(1), Article e016982. <https://doi.org/10.1136/bmjopen-2017-016982>
- Dahan, S., Behrbalk, P., Stolovy, T., & Greenberger, C. (2016). Improving adherence in hospitalized patients diagnosed with schizophrenia: An integrative one-on-one intervention. *Archives of Psychiatric Nursing*, 30(6), 660–665. <https://doi.org/10.1016/j.apnu.2016.03.002>
- Daley, D. J., Deane, K. H. O., Gray, R. J., Clark, A. B., Pfeil, M., Sabanathan, K., & Worth, P. F. (2014). Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: A randomised controlled trial. *International Journal of Clinical Practice*, 68(8), 963–971. <https://doi.org/10.1111/ijcp.12439>
- de Barra, M., Scott, C., Johnston, M., De Bruin, M., Scott, N., Matheson, C., Bond, C., & Watson, M. (2019). Do pharmacy intervention reports adequately describe their interventions? A template for intervention description and replication analysis of reports included in a systematic review. *BMJ Open*, 9(12), Article e025511. <https://doi.org/10.1136/bmjopen-2018-025511>
- de Bruin, M., Black, N., Javornik, N., Viechtbauer, W., Eisma, M. C., Hartman-Boyce, J., Williams, A. J., West, R., Michie, S., & Johnston, M. (2021). Underreporting of the active content of behavioural interventions: A systematic review and meta-analysis of randomised trials of smoking cessation interventions. *Health Psychology Review*, 15(2), 195–213. <https://doi.org/10.1080/17437199.2019.1709098>
- Deeks, J. J., Higgins, J. P. T., Altman, D. G., Higgins, J. P. T., Thomas, J., Chandler, J., & Cumpston, M. (2019). Chapter 10: Analysing data and undertaking meta-analyses. In J. P. T. Higgins, J. Thomas, J. Chandler,

- M. Cumpston, T. Li, M. J. Page, & V. A. Welch (Eds.), *Cochrane Handbook for Systematic Reviews of Interventions* (Version 6.0 -updated July 2019). <https://training.cochrane.org/handbook>
- Department of Health and Social Care. (2012). *Long term conditions compendium of information: Third edition*. <https://www.gov.uk/government/publications/long-term-conditions-compendium-of-information-third-edition>
- DiMatteo, M. R., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002). Patient adherence and medical treatment outcomes: A meta-analysis. *Medical Care*, 40(9), 794–811. <https://doi.org/10.1097/00005650-200209000-00009>
- Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. *BMJ*, 315(7109), 629–634. <https://doi.org/10.1136/bmj.315.7109.629>
- Elliott, R. A., Boyd, M. J., Salema, N-E., Davies, J., Barber, N., Mehta, R. L., & Tanajewski, L. (2016). Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: A pragmatic randomised controlled trial of the New Medicine Service. *BMJ Quality & Safety*, 25(10), 747–758. <https://doi.org/10.1136/bmjqs-2015-004400>
- European Patients Forum. (2015). *Adherence and concordance EDF position paper*. https://www.eu-patient.eu/globalassets/policy/adherence-compliance-concordance/adherence-paper-final-rev_external.pdf
- Ferguson, A., Ibrahim, F. A., Thomas, V., Weinman, J., Simpson, C., Cope, A. P., & Scott, D. L. (2015). Improving medication adherence in rheumatoid arthritis (RA): A pilot study. *Psychology, Health & Medicine*, 20(7), 781–789. <https://doi.org/10.1080/13548506.2015.1009917>
- Foot, H., La Caze, A., Gujral, G., & Cottrell, N. (2016). The necessity–concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis. *Patient Education and Counseling*, 99(5), 706–717. <https://doi.org/10.1016/j.pec.2015.11.004>
- Geurts, M. M. E., Stewart, R. E., Brouwers, J. R. B. J., de Graeff, P. A., & de Gier, J. J. (2015). Patient beliefs about medicines and quality of life after a clinical medication review and follow-up by a pharmaceutical care plan: A study in elderly polypharmacy patients with a cardiovascular disorder. *Journal of Pharmaceutical Health Services Research*, 6(4), 171–176. <https://doi.org/10.1111/jphs.12104>
- Goff, S. L., Mazor, K. M., Meterko, V., Dodd, K., & Sabin, J. (2008). Patients' beliefs and preferences regarding doctors' medication recommendations. *Journal of General Internal Medicine*, 23(3), 236–241. <https://doi.org/10.1007/s11606-007-0470-3>
- Gonzalez, J. S., Shreck, E., Psaros, C., & Safren, S. A. (2015). Distress and type 2 diabetes-treatment adherence: A mediating role for perceived control. *Health Psychology*, 34(5), 505–513. <https://doi.org/10.1037/hea0000131>
- Gray, R., Leese, M., Bindman, J., Becker, T., Burti, L., David, A., Gournay, K., Kikkert, M., Koeter, M., Puschner, B., Schene, A., Thornicroft, G., & Tansella, M. (2006). Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. *British Journal of Psychiatry*, 189(6), 508–514. <https://doi.org/10.1192/bjp.bp.105.019489>
- Gujral, G., Winckel, K., Nissen, L. M., & Cottrell, W. N. (2014). Impact of community pharmacist intervention discussing patients' beliefs to improve medication adherence. *International Journal of Clinical Pharmacy*, 36(5), 1048–1058. <https://doi.org/10.1007/s11096-014-9993-y>
- Hagger, M. S., & Orbell, S. (2022). The common sense model of illness self-regulation: A conceptual review and proposed extended model. *Health Psychology Review*, 16(3), 347–377. <https://doi.org/10.1080/17437199.2021.1878050>
- Halligan, P. W., & Aylward, M. (2006). Beliefs: Shaping experience and understanding illness. In P. W. Halligan, & M. Aylward (Eds.), *The power of bc belief: Psychosocial influence on illness, disability and medicine* (pp. xi–xxvi). Oxford University Press.
- Hedges, L. V., & Olkin, I. (1984). Nonparametric estimators of effect size in meta-analysis. *Psychological Bulletin*, 96(3), 573–580. <https://doi.org/10.1037/0033-2909.96.3.573>
- Heller, M. K., Chapman, S. C., & Horne, R. (2015). Beliefs about medication predict the misattribution of a common symptom as a medication side effect—Evidence from an analogue online study. *Journal of Psychosomatic Research*, 79(6), 519–529. <https://doi.org/10.1016/j.jpsychores.2015.10.003>
- Heller, M. K., Chapman, S. C., & Horne, R. (2017). No blank slates: Pre-existing schemas about pharmaceuticals predict memory for side effects. *Psychology & Health*, 32(4), 402–421. <https://doi.org/10.1080/08870446.2016.1273355>
- Higgins, N., Livingston, G., & Katona, C. (2004). Concordance therapy: An intervention to help older people take antidepressants. *Journal of Affective Disorders*, 81(3), 287–291. <https://doi.org/10.1016/j.jad.2003.07.004>
- Hoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D. G., Barbour, V., Macdonald, H., Johnston, M., Lamb, S. E., Dixon-Woods, M., McCulloch, P., Wyatt, J. C., Chan, A. W., & Michie, S. (2014). Better reporting of interventions: Template for intervention description and replication (TIDieR) checklist and guide. *BMJ*, 348, Article g1687. <https://doi.org/10.1136/bmj.g1687>
- Hogan, T. P., Awad, A., & Eastwood, R. (1983). A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. *Psychological Medicine*, 13(1), 177–183. <https://doi.org/10.1017/S0033291700050182>
- Horne, R. (1997). Representations of medication and treatment: Advances in theory and measurement. In K. J. Petrie, & J. A. Weinman (Eds.), *Perceptions of health and illness: Current research and applications* (pp. 155–188). Harwood Academic Publishers.
- Horne, R., Chapman, S. C., Parham, R., Freemantle, N., Forbes, A., & Cooper, V. (2013). Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: A meta-analytic review of the Necessity–Concerns Framework. *PLoS ONE*, 8(12), Article e80633. <https://doi.org/10.1371/journal.pone.0080633>
- Horne, R., Cooper, V., Wileman, V., & Chan, A. (2019). Supporting adherence to medicines for long-term conditions. *European Psychologist*, 24(1), 82–96. <https://doi.org/10.1027/1016-9040/a000353>
- Horne, R., & Hankins, M. (2008). *The Medication Adherence Report Scale (MARS): A new measurement tool for eliciting patients' reports of non-adherence*. The School of Pharmacy, University of London.
- Horne, R., & Weinman, J. (1999). Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *Journal of Psychosomatic Research*, 47(6), 555–567. [https://doi.org/10.1016/S0022-3999\(99\)00057-4](https://doi.org/10.1016/S0022-3999(99)00057-4)
- Horne, R., Weinman, J., Barber, N., Elliott, R., Morgan, M., Cribb, A., & Kellar, I. (2005). *Concordance, adherence and compliance in medicine taking* (pp. 40–46). NCCSDO.
- Horne, R., Weinman, J., & Hankins, M. (1999). The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology & Health*, 14(1), 1–24. <https://doi.org/10.1080/08870449908407311>
- Hunter, J. E., & Schmidt, F. L. (2000). Fixed effects vs. random effects meta-analysis models: Implications for cumulative research knowledge. *International Journal of Selection and Assessment*, 8(4), 275–292. <https://doi.org/10.1111/1468-2389.00156>
- Ioannidis, J. P., & Trikalinos, T. A. (2007). The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey. *Canadian Medical Association Journal*, 176(8), 1091–1096. <https://doi.org/10.1503/cmaj.060410>
- Jimby, B., & Jose, J. (2011). Patient medication adherence: Measures in daily practice. *Oman Medical Journal*, 26(3), 155–159. <https://doi.org/10.5001/omj.2011.38>
- Kassavou, A., & Sutton, S. (2018). Automated telecommunication interventions to promote adherence to cardio-metabolic medications: Meta-analysis of effectiveness and meta-regression of behaviour change techniques. *Health Psychology Review*, 12(1), 25–42. <https://doi.org/10.1080/17437199.2017.1365617>

- Keenum, A. J., DeVoe, J. E., Chisolm, D. J., & Wallace, L. S. (2012). Generic medications for you, but brand-name medications for me. *Research in Social and Administrative Pharmacy*, 8(6), 574–578. <https://doi.org/10.1016/j.sapharm.2011.12.004>
- Kemp, R., Hayward, P., Applewhaite, G., Everitt, B., & David, A. (1996). Compliance therapy in psychotic patients: Randomised controlled trial. *BMJ*, 312(7027), 345–349. <https://doi.org/10.1136/bmj.312.7027.345>
- Kooy, M. J., Van Geffen, E. C. G., Heerdink, E. R., Van Dijk, L., & Bouvy, M. L. (2015). Patients' general satisfaction with telephone counseling by pharmacists and effects on satisfaction with information and beliefs about medicines: Results from a cluster randomized trial. *Patient Education and Counseling*, 98(6), 797–804. <https://doi.org/10.1016/j.pec.2015.02.020>
- Krasnoryadtseva, A., Dalbeth, N., & Petrie, K. (2020). Does seeing personal medical images change beliefs about illness and treatment in people with gout? A randomised controlled trial. *Psychology & Health*, 35(1), 107–123. <https://doi.org/10.1080/08870446.2019.1626396>
- Lakshminarayana, R., Wang, D., Burn, D., Chaudhuri, K. R., Galtrey, C., Guzman, N. V., & Hellman, B. (2017). Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease. *NPJ Parkinson's Disease*, 3(1), Article 2. <https://doi.org/10.1038/s41531-016-0003-z>
- Leventhal, H., Brissette, I., & Leventhal, E. A. (2003). The common-sense model of self-regulation of health and illness. In L. D. Cameron, H. Leventhal (Eds.), *The self-regulation of health and illness behaviour* (pp. 42–65). Routledge.
- Lin, E. C.-L., Chan, C. H., Shao, W.-C., Lin, M.-F., Shiau, S., Mueser, K. T., & Huang, S.-C. (2013). A randomized controlled trial of an adapted Illness Management and Recovery program for people with schizophrenia awaiting discharge from a psychiatric hospital. *Psychiatric Rehabilitation Journal*, 36(4), 243–249. <https://doi.org/10.1037/prj0000013>
- Lin, E. H., Von Korff, M., Ludman, E. J., Rutter, C., Bush, T. M., Simon, G. E., Unützer, J., Walker, E., & Katon, W. J. (2003). Enhancing adherence to prevent depression relapse in primary care. *General Hospital Psychiatry*, 25(5), 303–310. [https://doi.org/10.1016/S0163-8343\(03\)00074-4](https://doi.org/10.1016/S0163-8343(03)00074-4)
- Linn, A. J., van Dijk, L., van Weert, J. C., Gebeyehu, B. G., van Bodegraven, A. A., & Smit, E. G. (2018). Creating a synergy effect: A cluster randomized controlled trial testing the effect of a tailored multimedia intervention on patient outcomes. *Patient Education and Counseling*, 101(8), 1419–1426. <https://doi.org/10.1016/j.pec.2018.03.017>
- Linn, A. J., van Weert, J. C., Gebeyehu, B. G., Sanders, R., Diviani, N., Smit, E. G., & van Dijk, L. (2019). Patients' online information-seeking behavior throughout treatment: The impact on medication beliefs and medication adherence. *Health Communication*, 34(12), 1461–1468. <https://doi.org/10.1080/10410236.2018.1500430>
- MacDonald, L., Chapman, S., Syrett, M., Bowskill, R., & Horne, R. (2016). Improving medication adherence in bipolar disorder: A systematic review and meta-analysis of 30 years of intervention trials. *Journal of Affective Disorders*, 194, 202–221. <https://doi.org/10.1016/j.jad.2016.01.002>
- Maneesakorn, S., Robson, D., Gournay, K., & Gray, R. (2007). An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand. *Journal of Clinical Nursing*, 16(7), 1302–1312. <https://doi.org/10.1111/j.1365-2702.2007.01786.x>
- Mårdby, A.-C. (2008). *General beliefs about medicines among pharmacy clients, healthcare students and professionals-group differences and association with adherence*. Institute of Medicine. Dept of Public Health and Community Medicine.
- Marques, M., Wright, A., Johnston, M., West, R., Hastings, J., Zhang, L., & Michie, S. (2023). The behaviour change technique ontology: Transforming the behaviour change technique taxonomy v1. <https://doi.org/10.31234/osf.io/vxypn>
- Mazor, K. M., Baril, J., Dugan, E., Spencer, F., Burgwinkle, P., & Gurwitz, J. H. (2007). Patient education about anticoagulant medication: Is narrative evidence or statistical evidence more effective? *Patient Education and Counseling*, 69(1–3), 145–157. <https://doi.org/10.1016/j.pec.2007.08.010>
- McManus, R. J., Mant, J., Franssen, M., Nickless, A., Schwartz, C., Hodgkinson, J., Bradburn, P., Farmer, A., Grant, S., Greenfield, S. M., Heneghan, C., Jowett, S., Martin, U., Milner, S., Monahan, M., Mort, S., Ogburn, E., Perera-Salazar, R., Shah, S. A., ... & the TASMINH4 investigators. (2018). Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): An unmasked randomised controlled trial. *The Lancet*, 391(10124), 949–959. [https://doi.org/10.1016/S0140-6736\(18\)30309-X](https://doi.org/10.1016/S0140-6736(18)30309-X)
- Michie, S., Richardson, M., Johnston, M., Abraham, C., Francis, J., Hardeman, W., Eccles, M. P., Cane, J., & Wood, C. E. (2013). The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: Building an international consensus for the reporting of behavior change interventions. *Annals of Behavioral Medicine*, 46(1), 81–95. <https://doi.org/10.1007/s12160-013-9486-6>
- Molloy, G. J., Graham, H., & McGuinness, H. (2012). Adherence to the oral contraceptive pill: A cross-sectional survey of modifiable behavioural determinants. *BMC Public Health*, 12(1), Article 838. <https://doi.org/10.1186/1471-2458-12-838>
- Montes, J. M., Maurino, J., Diez, T., & Saiz-Ruiz, J. (2010). Telephone-based nursing strategy to improve adherence to antipsychotic treatment in schizophrenia: A controlled trial. *International Journal of Psychiatry in Clinical Practice*, 14(4), 274–281. <https://doi.org/10.3109/13651501.2010.505343>
- Montes, J. M., Medina, E., Gomez-Beneyto, M., & Maurino, J. (2012). A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. *Psychiatry Research*, 200(2–3), 89–95. <https://doi.org/10.1016/j.psychres.2012.07.034>
- Morisky, D. E., Bowler, M. H., & Finlay, J. S. (1982). An educational and behavioral approach toward increasing patient activation in hypertension management. *Journal of Community Health*, 7(3), 171–182. <https://doi.org/10.1007/BF01325513>
- Morisky, D. E., Green, L. W., & Levine, D. M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. *Medical Care*, 24(1), 67–74.
- Morrissey, E. C., Corbett, T. K., Walsh, J. C., & Molloy, G. J. (2016). Behavior change techniques in apps for medication adherence: A content analysis. *American Journal of Preventive Medicine*, 50(5), e143–e146. <https://doi.org/10.1016/j.amepre.2015.09.034>
- Moshkovska, T., Stone, M. A., Smith, R. M., Bankart, J., Baker, R., & Mayberry, J. F. (2011). Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: Results from an exploratory randomized controlled trial. *Inflammatory Bowel Diseases*, 17(9), 1874–1881. <https://doi.org/10.1002/ibd.21570>
- Newby, K., Teah, G., Cooke, R., Li, X., Brown, K., Salisbury-Finch, B., Kwah, K., Bartle, N., Curtis, K., Fulton, E., Parsons, J., Dusseldorp, E., & Williams, S. (2021). Do automated digital health behaviour change interventions have a positive effect on self-efficacy? A systematic review and meta-analysis. *Health Psychology Review*, 15(1), 140–158. <https://doi.org/10.1080/17437199.2019.1705873>
- Nguyen, T.-M.-U., La Caze, A., & Cottrell, N. (2016). Validated adherence scales used in a measurement-guided medication management approach to target and tailor a medication adherence intervention: A randomised controlled trial. *BMJ Open*, 6(11), Article e013375. <https://doi.org/10.1136/bmjopen-2016-013375>
- NHS. (2017). *Long term physical health condition*. http://www.datadictionary.nhs.uk/data_dictionary/nhs_business_definitions/l/long_term_physical_health_condition_de.asp?shownav=1
- Nie, B., Chapman, S. C., Chen, Z., Wang, X., & Wei, L. (2019). Utilization of the beliefs about medicine questionnaire and prediction of medication adherence in China: A systematic review and meta-analysis. *Journal of Psychosomatic Research*, 122, 54–68. <https://doi.org/10.1016/j.jpsychores.2019.03.184>

- Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keenanasseril, A., Agoristas, T., Mistry, N., Iorio, A., Jack, S., Sivaramalingam, B., Iserman, E., Mustafa, R. A., Jedraszewski, D., Cotoi, C., & Haynes, R. B. (2014). Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews*, 2014(11), Article CD000011. <https://doi.org/10.1002/14651858.CD000011.pub4>
- Norcross, J. C., & Lambert, M. J. (2018). Psychotherapy relationships that work III. *Psychotherapy*, 55(4), 303–315. <https://doi.org/10.1037/pst0000193>
- Nunes, V., Neilson, J., O'flynn, N., Calvert, N., Kuntze, S., Smithson, H., Benson, J., Blair, J., Bowser, A., Clyne, W., Crome, P., Haddad, P., Hemingway, S., Horne, R., Johnson, S., Kelly, S., Packham, B., Patel, M., & Steel, J. (2009). Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence. National Collaborating Centre for Primary Care and Royal College of General Practitioners. <https://www.nice.org.uk/guidance/cg76/evidence/full-guideline-242062957>
- O'Carroll, R. E., Chambers, J. A., Dennis, M., Sudlow, C., & Johnston, M. (2013). Improving adherence to medication in stroke survivors: A pilot randomised controlled trial. *Annals of Behavioral Medicine*, 46(3), 358–368. <https://doi.org/10.1007/s12160-013-9515-5>
- O'Donnell, C., Donohoe, G., Sharkey, L., Owens, N., Migone, M., Harries, R., & O'Callaghan, E. (2003). Compliance therapy: A randomised controlled trial in schizophrenia. *BMJ*, 327(7419), Article 834. <https://doi.org/10.1136/bmj.327.7419.834>
- Orom, H., Underwood, W., Cheng, Z., Homish, D. L., & Scott, I. Y. (2018). Relationships as medicine: Quality of the physician–patient relationship determines physician influence on treatment recommendation adherence. *Health Services Research*, 53(1), 580–596. <https://doi.org/10.1111/1475-6773.12629>
- Östbring, M. J., Eriksson, T., Petersson, G., & Hellström, L. (2014). Medication beliefs and self-reported adherence—results of a pharmacist's consultation: A pilot study. *European Journal of Hospital Pharmacy*, 21(2), 102–107. <https://doi.org/10.1136/ejhp-2013-000402>
- Osterberg, L., & Blaschke, T. (2005). Adherence to medication. *New England Journal of Medicine*, 353(5), 487–497. <https://doi.org/10.1056/NEJMr050100>
- Pakpour, A. H., Gholami, M., Esmaili, R., Naghibi, S. A., Updegraff, J. A., Molloy, G. J., & Dombrowski, S. U. (2015). A randomized controlled multimodal behavioral intervention trial for improving antiepileptic drug adherence. *Epilepsy & Behavior*, 52, 133–142. <https://doi.org/10.1016/j.yebeh.2015.08.036>
- Pakpour, A. H., Modabbernia, A., Lin, C.-Y., Saffari, M., Asl, M. A., & Webb, T. L. (2017). Promoting medication adherence among patients with bipolar disorder: a multicenter randomized controlled trial of a multifaceted intervention. *Psychological Medicine*, 47(14), 2528–2539. <https://doi.org/10.1017/S003329171700109X>
- Perera, A. I., Thomas, M. G., Moore, J. O., Faasse, K., & Petrie, K. J. (2014). Effect of a smartphone application incorporating personalized health-related imagery on adherence to antiretroviral therapy: A randomized clinical trial. *AIDS Patient Care and STDs*, 28(11), 579–586. <https://doi.org/10.1089/apc.2014.0156>
- Peters, G.-J. Y., De Bruin, M., & Crutzen, R. (2015). Everything should be as simple as possible, but no simpler: Towards a protocol for accumulating evidence regarding the active content of health behaviour change interventions. *Health Psychology Review*, 9(1), 1–14. <https://doi.org/10.1080/17437199.2013.848409>
- Petrie, K. J., Perry, K., Broadbent, E., & Weinman, J. (2012). A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication. *British Journal of Health Psychology*, 17(1), 74–84. <https://doi.org/10.1111/j.2044-8287.2011.02033.x>
- Petrie, K. J., & Rief, W. (2019). Psychobiological mechanisms of placebo and nocebo effects: Pathways to improve treatments and reduce side effects. *Annual Review of Psychology*, 70(1), 599–625. <https://doi.org/10.1146/annurev-psych-010418-102907>
- Polack, J., Jorgenson, D., & Robertson, P. (2008). Evaluation of different methods of providing medication-related education to patients following myocardial infarction. *Canadian Pharmacists Journal*, 141(4), 241–247. [https://doi.org/10.3821/1913-701X\(2008\)141\[241:EODMOP\]2.0.CO;2](https://doi.org/10.3821/1913-701X(2008)141[241:EODMOP]2.0.CO;2)
- Prasetya, H., Murti, B., Anantanyu, S., & Syamsulhadi, M. (2018). The effect of hypnosis on adherence to antituberculosis drugs using the health belief model. *International Journal of Clinical and Experimental Hypnosis*, 66(2), 211–227. <https://doi.org/10.1080/00207144.2018.1421361>
- Riaz, S., & Nielsen, J. D. J. (2019). A pilot study of a text messaging intervention to modify illness and medication beliefs among patients diagnosed with inflammatory bowel disease. *Journal of Technology in Behavioral Science*, 4(1), 42–52. <https://doi.org/10.1007/s41347-018-0083-1>
- Rickles, N. M., Svarstad, B. L., Statz-Paynter, J. L., Taylor, L. V., & Kobak, K. A. (2005). Pharmacist telemonitoring of antidepressant use: Effects on pharmacist–patient collaboration. *Journal of the American Pharmacists Association*, 45(3), 344–353. <https://doi.org/10.1331/1544345054003732>
- Sabaté, E. (2003). *Adherence to long-term therapies: Evidence for action*. World Health Organization.
- Samdal, G. B., Eide, G. E., Barth, T., Williams, G., & Meland, E. (2017). Effective behaviour change techniques for physical activity and healthy eating in overweight and obese adults: systematic review and meta-regression analyses. *International Journal of Behavioral Nutrition and Physical Activity*, 14(1), Article 42. <https://doi.org/10.1186/s12966-017-0494-y>
- Scala, D., Menditto, E., Caruso, G., Monetti, V. M., Orlando, V., Guerriero, F., & Buonomo, G. (2018). Are you more concerned about or relieved by medicines? An explorative randomized study of the impact of telephone counseling by pharmacists on patients' beliefs regarding medicines and blood pressure control. *Patient Education and Counseling*, 101(4), 679–686. <https://doi.org/10.1016/j.pec.2017.12.006>
- Schulz, M., Gray, R., Spiekermann, A., Abderhalden, C., Behrens, J., & Driessen, M. (2013). Adherence therapy following an acute episode of schizophrenia: A multi-centre randomised controlled trial. *Schizophrenia Research*, 146(1–3), 59–63. <https://doi.org/10.1016/j.schres.2013.01.028>
- Sethares, K. A., & Elliott, K. (2004). The effect of a tailored message intervention on heart failure readmission rates, quality of life, and benefit and barrier beliefs in persons with heart failure. *Heart & Lung*, 33(4), 249–260. <https://doi.org/10.1016/j.hrtlng.2004.03.005>
- Shahin, W., Kennedy, G. A., & Stupans, I. (2019). The impact of personal and cultural beliefs on medication adherence of patients with chronic illnesses: A systematic review. *Patient Preference and Adherence*, 13, 1019–1035. <https://doi.org/10.2147/PPA.S212046>
- Simpson, S. H., Eurich, D. T., Majumdar, S. R., Padwal, R. S., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2006). A meta-analysis of the association between adherence to drug therapy and mortality. *BMJ*, 333(7557), Article 15. <https://doi.org/10.1136/bmj.38875.675486.55>
- Sterne, J., Savović, J., Page, M., Elbers, R., Blencowe, N., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., Emberson, J. R., Hernán, M. A., Hopewell, S., Hróbjartsson, A., Junqueira, D. R., Jüni, P., Kirkham, J. J., Lasserson, T., Li, T., ... Higgins, J. P. T. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. *BMJ*, 366, Article 14898. <https://doi.org/10.1136/bmj.14898>
- Terrin, N., Schmid, C. H., Lau, J., & Olkin, I. (2003). Adjusting for publication bias in the presence of heterogeneity. *Statistics in Medicine*, 22(13), 2113–2126. <https://doi.org/10.1002/sim.1461>
- Thompson, K., Kulkarni, J., & Sergejew, A. A. (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. *Schizophrenia Research*, 42(3), 241–247. <https://doi.org/10.1016/S0920-9964>
- Thornton, A., & Lee, P. (2000). Publication bias in meta-analysis: Its causes and consequences. *Journal of Clinical Epidemiology*, 53(2), 207–216. [https://doi.org/10.1016/S0895-4356\(99\)00161-4](https://doi.org/10.1016/S0895-4356(99)00161-4)

- Tsang, H. W., & Wong, T. K. S. (2005). The effects of a compliance therapy programme on Chinese male patients with schizophrenia. *Asian Journal of Nursing Studies*, 8(2), 47–61.
- Unk, J. A., & Brasington, R. (2014). Efficacy study of multimedia rheumatoid arthritis patient education program. *Journal of the American Association of Nurse Practitioners*, 26(7), 370–377. <https://doi.org/10.1002/2327-6924.12064>
- Uslu, E., & Buldukoglu, K. (2019). Randomized controlled trial of the effects of nursing care based on a telephone intervention for medication adherence in schizophrenia. *Perspectives in Psychiatric Care*, 56(1), 63–71. <https://doi.org/10.1111/ppc.12376>
- Uzenoff, S. R., Perkins, D. O., Hamer, R. M., Wiesen, C. A., & Penn, D. L. (2008). A preliminary trial of adherence-coping-education (ACE) therapy for early psychosis. *Journal of Nervous & Mental Disease*, 196(7), 572–575. <https://doi.org/10.1097/NMD.0b013e31817d01a5>
- van der Laan, D. M., Elders, P. J. M., Boons, C. C. L. M., Nijpels, G., van Dijk, L., & Hugtenburg, J. G. (2018). Effectiveness of a patient-tailored, pharmacist-led intervention program to enhance adherence to antihypertensive medication: The CATI study. *Frontiers in Pharmacology*, 9, <https://doi.org/10.3389/fphar.2018.01057>
- Vergouwen, A. C., Burger, H., Verheij, T. J., & Koerselman, F. (2009). Improving Patients' Beliefs About Antidepressants in Primary Care. *The Primary Care Companion to The Journal of Clinical Psychiatry*, 11(2), 48–52. <https://doi.org/10.4088/PCC.08m00686>
- von Bormann, S., Robson, D., & Gray, R. (2015). Adherence therapy following acute exacerbation of schizophrenia: A randomised controlled trial in Thailand. *International Journal of Social Psychiatry*, 61(1), 3–9. <https://doi.org/10.1177/0020764014529099>
- Zwikker, H. E., van den Ende, C. H., van Lankveld, W. G., den Broeder, A. A., van den Hoogen, F. H., van de Mosselaar, B., & van Dulmen, S. (2014). Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: A randomized controlled trial. *Patient Education and Counseling*, 94(3), 356–361. <https://doi.org/10.1016/j.pec.2013.12.002>

Received September 8, 2022

Revision received May 18, 2023

Accepted May 20, 2023 ■

E-Mail Notification of Your Latest Issue Online!

Would you like to know when the next issue of your favorite APA journal will be available online? This service is now available to you. Sign up at <https://my.apa.org/portal/alerts/> and you will be notified by e-mail when issues of interest to you become available!